<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFTIZOXIME SODIUM</span><br/>(sef-ti-zox'eem)<br/><span class="topboxtradename">Cefizox<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic third-generation cephalosporin antibiotic. Preferentially binds to one or more of the penicillin-binding proteins
         (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis,
         thus killing the bacterium. Spectrum of activity similar to that of cefotaxime. Generally resistant to inactivation by beta-lactamases
         that act principally as cephalosporinases and penicillinases.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>
<i>Clostridium difficile,</i> enterococci including <i>Streptococcus faecalis,</i> and most strains of <i>Listeria monocytogenes</i> are resistant to ceftizoxime. Incompatible with the aminoglycoside antibiotics. Evidence of partial cross-allergenicity among
         cephalosporins and other beta-lactamase antibiotics has been reported. It is used for gram-negative bacillary meningitis and
         drug-resistant <i>Enterobacteriaceae</i>. Effectively treats endocarditis, bone and joint infections, gonorrhea and gynecologic infections including PID, <i>Escherichia coli</i> infections, <i>Haemophilus influenzae</i> infections, intra-abdominal infections, meningitis, osteomyelitis, lower respiratory tract infections, <i>Serratia</i> sp. infections, septicemia and skin infections, urinary tract infections, and is used for surgical prophylaxis, reducing
         or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Infections caused by susceptible organisms in lower respiratory tract, skin and skin structures, urinary tract, bones and
         joints; also used to treat intra-abdominal infections, pelvic inflammatory disease, uncomplicated gonorrhea, meningitis <i>(Haemophilus influenzae, Streptococcus pneumoniae),</i> and for surgical prophylaxis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Meningitis caused by <i>Neisseria meningitidis</i> and <i>E. coli.</i>
</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and other beta-lactam antibiotics; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q812h, up to 2 g q4h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span>
<i><img src="../images/special/greaterorequal.gif"/>6 mo,</i> 50 mg/kg q68h, up to 200 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute as follows with sterile water for injection: add 1.5 mL to 500 mg to yield 280 mg/mL; add 3 mL to 1 g or 6 mL
            to 2 g to yield 270 mg/mL.
         </li>
<li>Give deep IM into a large muscle. Give no more than 1 g into a single injection site.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span>  Reconstitute each 1 g with 10 mL sterile water. Shake well.  <span class="methodtype">Intermittent:</span> Further dilute in 50100 mL D5W, NS, D5/NS, D5/.45% NaCl, RL, or other compatible IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.  <span class="methodtype">Intermittent:</span> Give over 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>.  <span class="incompattype"> Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>filgrastim.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Protect from light. Consult manufacturer's directions concerning storage of reconstituted solutions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, phlebitis, vaginitis, pain and induration at injection site, paresthesia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, <span class="speceff-life">pseudomembranous colitis</span>. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Ceftizoxime causes false-positive <span class="alt">direct Coombs' test</span> (may interfere with <span class="alt">cross-matching procedures</span> and <span class="alt">hematologic studies).</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of ceftizoxime. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1 h after IM or IV. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 8090% excreted unchanged in urine in 24 h; small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 2560 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity reactions to cephalosporins, penicillin, or other drugs before therapy is instituted.
            Report to physician history of allergy, particularly to drugs.
         </li>
<li>Lab tests: Perform culture and sensitivity tests before initiation of therapy and periodically during therapy if indicated.
            Therapy may be instituted pending test results.
         </li>
<li>Be alert to symptoms of hypersensitivity reaction (see Appendix F). Serious reactions may require emergency measures.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report loose stools or diarrhea promptly.</li>
<li>Report any signs or symptoms of hypersensitivity (see Appendix F) promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>